Pfizer Inc. reported a 61% EASI-75 response on monthly tilrekimig versus 9.1% on placebo at Week 16 in a Phase 2 atopic dermatitis study.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.